A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
TaiRx, Inc.
HistoSonics, Inc.
Teclison Ltd.
Seagen Inc.
Pfizer
AstraZeneca
BeOne Medicines
AstraZeneca
Teclison Ltd.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Bayer
Zymeworks BC Inc.
Bristol-Myers Squibb
TaiRx, Inc.
7 Hills Pharma, LLC
Nammi Therapeutics Inc
RayzeBio, Inc.
Beijing Biotech
Parabilis Medicines, Inc.
Compass Therapeutics
Tvardi Therapeutics, Incorporated
AstraZeneca
Genentech, Inc.
Replimune, Inc.
Alnylam Pharmaceuticals
Boston Scientific Corporation
Aptamer Sciences, Inc.
Hoffmann-La Roche
3D Medicines
Guangzhou FineImmune Biotechnology Co., LTD.
Wuhan Ammunition Life-tech Co., Ltd
Akeso
Shanghai Henlius Biotech
Exelixis
Akeso
ViroMissile, Inc.
SEED Therapeutics, Inc.
Daiichi Sankyo
DualityBio Inc.
MacroGenics
SAPU NANO (US) LLC
Jiangsu Simcere Pharmaceutical Co., Ltd.
Guerbet
Wondercel Biotech (ShenZhen)
inTumo Therapeutics, Inc.
Replimune, Inc.
AstraZeneca
Abbisko Therapeutics Co, Ltd
Newish Technology (Beijing) Co., Ltd.
Shanghai AbelZeta Ltd.